{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T01:19:23Z","timestamp":1794791963402,"version":"4.9.1"},"reference-count":53,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Psychogeriatrics"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Agitation in Alzheimer's disease (AD) is clinically heterogeneous. Patients who meet the same syndromic definition can differ in the behaviour of greatest concern, the factors that precipitate or sustain it, the risks involved and their response to treatment. Randomised trials are essential for estimating average treatment effects; individual treatment selection also requires patient\u2010specific clinical information. This review considers patient\u2010specific clinical formulation as a practical way to connect group\u2010level evidence with individual treatment decisions. The formulation makes explicit what is being treated, which contributors are plausible, which contextual or reversible factors matter, what outcome would count as meaningful improvement and when treatment should be changed or stopped. Treatment response then becomes additional clinical information: early benefit, adverse effects or an unexpected course may support or call into question the initial formulation. Non\u2010pharmacological care and treatment of reversible causes remain the foundation of management, with medication reserved for agitation that is severe, persistent, dangerous or highly distressing. For Japan, we propose a formulation summary as a prototype for shared documentation across care settings; its feasibility and clinical value require prospective evaluation. Moving beyond group averages entails applying evidence more carefully to the needs of the individual patient.<\/jats:p>","DOI":"10.1111\/psyg.70220","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:39:59Z","timestamp":1790210399000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient\u2010Specific Clinical Formulation for Agitation in Alzheimer's Disease: Beyond Group\u2010Level Evidence"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5952-6141","authenticated-orcid":false,"given":"Shunichiro","family":"Shinagawa","sequence":"first","affiliation":[{"name":"Department of Psychiatry The Jikei University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8731-9887","authenticated-orcid":false,"given":"Tomoyuki","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Psychiatry The Jikei University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610222001041"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2291966"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010210105"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010215670"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610214001963"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/S104161022200103X"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h369"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.inpsyc.2026.100241"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010150869"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010170412"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251340402"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010240256"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010180304"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12961"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12091365"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.inpsyc.2025.100056"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12335"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01109"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852924000427"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.10.005"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S57522"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.72"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2012.01.015"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000363500"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.71116"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.45175"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.04.013"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.113.141119"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4065"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061240"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.07111779"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013304.pub2"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.15.1934"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.08121844"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.09.009"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.3810"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14282"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/25424823251334054"},{"key":"e_1_2_14_40_1","unstructured":"US Food and Drug Administration \u201cREXULTI (brexpiprazole) Tablets: Prescribing Information for Agitation Associated with Dementia due to Alzheimer's Disease \u201d2023 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/205422s009lbl.pdf."},{"key":"e_1_2_14_41_1","unstructured":"Pharmaceuticals and Medical Devices Agency \u201cRexulti Tablets and Orally Disintegrating Tablets: Review Report and Prescribing Information for Agitation Associated with Alzheimer\u2010Type Dementia \u201d2024 https:\/\/www.pmda.go.jp\/PmdaSearch\/rdDetail\/iyaku\/1179058F1020_1?user=1."},{"key":"e_1_2_14_42_1","unstructured":"US Food and Drug Administration \u201cFDA Approves First Drug to Treat Agitation Symptoms Associated With Dementia Due to Alzheimer's Disease \u201d2023 https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010drug\u2010treat\u2010agitation\u2010symptoms\u2010associated\u2010dementia\u2010due\u2010alzheimers\u2010disease."},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.93"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10214"},{"key":"e_1_2_14_45_1","unstructured":"US Food and Drug Administration \u201cAUVELITY (Dextromethorphan Hydrobromide and Bupropion Hydrochloride) Extended\u2010Release Tablets: Prescribing Information \u201d2026 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/215430s009s018lbl.pdf."},{"key":"e_1_2_14_46_1","unstructured":"US Food and Drug Administration \u201cFDA Approves First Non\u2010Antipsychotic Drug to Treat Agitation Associated with Dementia \u201d2026 https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010non\u2010antipsychotic\u2010drug\u2010treat\u2010agitation\u2010associated\u2010dementia."},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003945.pub4"},{"issue":"1","key":"e_1_2_14_48_1","first-page":"17","article-title":"Deprescribing Antipsychotics for Behavioural and Psychological Symptoms of Dementia and Insomnia: Evidence\u2010Based Clinical Practice Guideline","volume":"64","author":"Bjerre L. M.","year":"2018","journal-title":"Canadian Family Physician"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114058"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/13872877261415637"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.70143"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1159\/000099472"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4704"},{"key":"e_1_2_14_54_1","volume-title":"Guidelines for Psychotropic Drug Use for Behavioral and Psychological Symptoms of Dementia for Primary Care Physicians and Dementia Support Physicians","author":"Ministry of Health, Labour and Welfare","year":"2025"}],"container-title":["Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/psyg.70220","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/psyg.70220","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/psyg.70220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T00:31:05Z","timestamp":1794789065000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/psyg.70220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1111\/psyg.70220"],"URL":"https:\/\/doi.org\/10.1111\/psyg.70220","archive":["Portico"],"relation":{},"ISSN":["1346-3500","1479-8301"],"issn-type":[{"value":"1346-3500","type":"print"},{"value":"1479-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"2026-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70220"}}